Brian H. Kushner, MD
Memorial Sloan Kettering Cancer Center
8
3
8
N/A
0
11
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+16 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (8)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Shakeel Modak, MD
Memorial Sloan Kettering Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Michael B Gill
Power Life Sciences Inc.
Shared therapeutic areas:
Steven A. Rosenberg, MD, PhD
NCI - Surgery Branch
Shared therapeutic areas:
Worked with same sponsors:
Zhenfeng Zhang, MD, PhD
Second Affiliated Hospital of Guangzhou Medical University
Shared therapeutic areas:
Steven A Rosenberg, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Worked with same sponsors:
Stanislaw R. Burzynski, MD, PhD
Burzynski Research Institute
Shared therapeutic areas:
John D. Hainsworth, MD
SCRI Development Innovations, LLC
Shared therapeutic areas:
Tanya Trippett, MD
Memorial Sloan Kettering Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Mark Levine, MD
Ontario Clinical Oncology Group (OCOG)
Shared therapeutic areas:
David Avigan, MD
Beth Israel Deaconess Medical Center
Shared therapeutic areas:
Worked with same sponsors:
Publications (0)
No publications found for this investigator.
Clinical Trials (8)
Showing 8 of 8 trials
A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma
Beta-Glucan and Monoclonal Antibody 3F8 in Treating Patients With Metastatic Neuroblastoma
Combination Chemotherapy and Radiation Therapy in Treating Patients With Peripheral Neuroectodermal Tumors, Ewing's Sarcoma, Wilms' Tumor, or Bone Cancer
Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer
Monoclonal Antibody Therapy Plus Sargramostin in Treating Patients With Advanced Neuroblastoma
Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors
Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma
Monoclonal Antibody 3F8 and GM-CSF in Treating Young Patients With High-Risk, Refractory or Relapsed Neuroblastoma
All 8 trials loaded